Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Cigna, Novartis strike outcomes-based Entresto deal

    Cigna Corp. (NYSE:CI) said Monday that it struck an outcomes-based pricing deal with Novartis AG (NYSE:NVS; SIX:NOVN) for heart failure drug Entresto sacubitril/valsartan.Cigna said the agreement ties financial terms to…

    Published on 2/8/2016
  • COMPANY NEWS: Management tracks

    Protein degradation newco C4 Therapeutics Inc. (Cambridge, Mass.) hired Andrew Phillips as CSO. He was senior director of the center for development of therapeutics at the Broad Institute of MIT and Harvard.Achillion …

    Published on 2/8/2016
  • COMPANY NEWS: NICE rebuffs Praluent, reverses course on Repatha

    The U.K.'s NICE issued draft guidance recommending against the use of Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) alone or in combination with lipid-…

    Published on 2/8/2016
  • COMPANY NEWS: Pfizer unveils post-merger management team

    Pfizer Inc. (NYSE:PFE) named the management team that is to lead the company after it completes its merger with Allergan plc (NYSE:AGN).Pfizer intends to combine its Global Innovative Pharma (GIP) and Vaccines, Oncology…

    Published on 2/8/2016
  • COMPANY NEWS: FDA issues CRL for Kalydeco

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) fell $5.11 to $86.61 on Friday after FDA issued a complete response letter for an sNDA seeking to expand the label of cystic fibrosis drug Kalydeco ivacaftor to include patients…

    Published on 2/5/2016
  • COMPANY NEWS: Gilead's Mansuri joining Sanofi

    Sanofi (Euronext:SAN; NYSE:SNY) hired Muzammil Mansuri as EVP of strategy and business development, effective Feb. 22. In the role, he also will be responsible for the pharma's Sanofi-Genzyme BioVentures corporate …

    Published on 2/5/2016
  • COMPANY NEWS: SciClone seeking alternatives

    SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) gained $0.65 to $8.76 on Friday after reporting late Thursday that it settled an investigation with the SEC and hired Lazard to help the company seek strategic alternatives. …

    Published on 2/5/2016
  • COMPANY NEWS: FDA panel backs cognitive dysfunction claim for Brintellix

    FDA's Psychopharmacologic Drugs Advisory Committee voted 8-2 on Wednesday that H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) provided substantial evidence to support an efficacy claim…

    Published on 2/4/2016
  • COMPANY NEWS: Tessier-Lavigne to become Stanford president

    Stanford University (Stanford, Calif.) hired Marc Tessier-Lavigne as president, effective Sept. 1. He will succeed John Hennessy, who last year announced plans to step down as president.Tessier-Lavigne has been …

    Published on 2/4/2016
  • COMPANY NEWS: Mersana, Takeda expand relationship

    Mersana Therapeutics Inc. (Cambridge, Mass.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) rights to co-develop Mersana's lead internal program, XMT-1522, a preclinical antibody-drug conjugate (ADC) targeting HER2…

    Published on 2/3/2016
  • COMPANY NEWS: Adaptimmune, GSK expand TCR deal for NY-ESO-1

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expanded a deal under which the companies are co-developing an autologous T cell receptor (TCR) therapy targeting cancer/testis …

    Published on 2/2/2016
  • COMPANY NEWS: Gilead still eyeing cancer, inflammation deals

    Gilead Sciences Inc. (NASDAQ:GILD) reported earnings that showed a continued reliance on HCV sales and company executives expressed interest in dealmaking to broaden Gilead's cancer and inflammatory portfolios."It's …

    Published on 2/2/2016
  • COMPANY NEWS: U.K. court invalidates Regeneron mouse patents

    Kymab Ltd. (Cambridge, U.K.) said the English High Court revoked two patents from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) protecting VelocImmune mice and humanized mouse antibodies derived from the mice. Regeneron …

    Published on 2/2/2016
  • COMPANY NEWS: Abbott buys diagnostics company Alere

    Abbott Laboratories (NYSE:ABT) is acquiring diagnostics play Alere Inc. (NYSE:ALR) for $56 per share in cash, or about $5.8 billion. Abbott said it will assume or refinance Alere's net debt of $2.6 billion. The …

    Published on 2/1/2016
  • COMPANY NEWS: Avalanche acquires Annapurna

    Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 …

    Published on 2/1/2016
  • COMPANY NEWS: Huya, Eisai strike deal for Chipscreen drug

    Huya Bioscience International LLC (San Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya has ex-China rights to the drug from Shenzhen Chipscreen …

    Published on 2/1/2016
  • COMPANY NEWS: Portola partners andexanet alfa in Japan

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE: PFE) to develop and commercialize Portola's andexanet alfa (PRT064445) in Japan. The recombinant …

    Published on 2/1/2016
  • COMPANY NEWS: Aetna, Novartis strike deal on Entresto

    Aetna Inc. (NYSE:AET) told BioCentury on Friday that it struck an outcomes-based pricing deal with Novartis AG (NYSE:NVS; SIX:NOVN) for heart failure drug Entresto sacubitril/valsartan.Novartis agreed to an undisclosed …

    Published on 1/29/2016
  • COMPANY NEWS: Allergan, AZ partner to develop antibiotic

    Allergan plc (NYSE:AGN) said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to develop ATM-AVI, a combination of antibiotics aztreonam and avibactam to treat Gram-negative infections.ATM-AVI was developed under a…

    Published on 1/29/2016
  • COMPANY NEWS: CHMP backs basket of therapies

    EMA's CHMP recommended marketing authorization of three new medicines Thursday and recommended label expansions for Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) and Revolade eltrombopag from Novartis AG (NYSE:…

    Published on 1/29/2016
  • COMPANY NEWS: FDA panel to discuss Acadia's Nuplazid for PDP

    FDA's Psychopharmacologic Drugs Advisory Committee will meet on March 29 to discuss an NDA for Nuplazid pimavanserin from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to treat Parkinson's disease psychosis. The NDA is …

    Published on 1/29/2016
  • COMPANY NEWS: Gilead promotes Milligan to CEO

    Gilead Sciences Inc. (NASDAQ:GILD) said President and COO John Milligan will be promoted to CEO and will join Gilead's board, effective March 10. Current Chairman and CEO John Martin will become executive chairman. …

    Published on 1/29/2016
  • COMPANY NEWS: Management tracks

    The EMD Serono unit of Merck KGaA (Xetra:MRK) named Gary Zieziula president and managing director for North America. Zieziula was EMD Serono's chief commercial officer. Immuno-oncology company Surface Oncology Inc. (…

    Published on 1/29/2016
  • COMPANY NEWS: Synergy submits plecanatide NDA

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said it submitted an NDA to FDA for plecanatide, a guanylate cyclase C (GCC; GUCY2C) agonist to treat chronic idiopathic constipation (CIC).Last year, plecanatide met the …

    Published on 1/29/2016
  • COMPANY NEWS: Breakthrough designation for AZ's Lynparza in CRPC

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA granted breakthrough therapy designation to Lynparza olaparib as monotherapy to treat metastatic castration-resistant prostate cancer. The designation covers CRPC patients …

    Published on 1/28/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993